Prosecution Insights
Last updated: November 04, 2026
Application No. 18/147,716

METHOD FOR PREPARING BIOCHIP AND BIOCHIP PREPARED THEREFROM

Final Rejection §103
Filed
Dec 29, 2022
Priority
Mar 18, 2022 — provisional 63/321,209 +3 more
Examiner
MACFARLANE, STACEY NEE
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novascope Biochips Inc.
OA Round
3 (Final)
54%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
452 granted / 843 resolved
-6.4% vs TC avg
Strong +40% interview lift
Without
With
+39.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
36 currently pending
Career history
885
Total Applications
across all art units

Statute-Specific Performance

§101
9.3%
-30.7% vs TC avg
§103
25.4%
-14.6% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
36.5%
-3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 843 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Claim 1 has been amended as requested in the amendment filed on 20 March 2026. Following the amendment, claims 1-20 are pending in the instant application. Claims 11-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions. Claims 1-10 are under examination in the instant office action. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. As currently amended, Claims 1-10 stand as being rejected under 35 U.S.C. 103 as being unpatentable over Dutta et al., (2020); Li et al., (2020); RayBiotech brochure, all made of record in the prior office action; as evidenced by BOC Sciences, What is Biotinylation and Biotinylated PEG? Article; Retrieved from https://peg.bocsci.com/resources/what-are-biotinylation-and-biotinylated-peg.html ; Retrieved on 10/20/2026. On pages 7-10 of Remarks filed 20 March 2026, Applicant traverses the rejection based upon different prior art references on the following grounds. Applicant asserts Dutta teaches away from the invention because it utilizes biotinylated PEG, in contrast to the present invention which teaches only biotin. Applicant asserts that the method of Dutta would not be successful without the 2000 Da PEG support. Applicant further states that, given biotin has a molecular weight of 244 Da and the molecular weight of Dutta’s bPEG is 2.244 kDa, thus it exceeds the molecular weight of the present application (Remarks pg. 4). Further, Dutta teaches that PEG is critically required to support the biotin molecules for interacting with the streptavidin. Lastly, Applicant argues that the claimed concentrations are critical to the invention (pg. 5). While all these arguments have been reviewed in full, they are not persuasive to overcome the rejection. First, the claims recite a method comprising coating a chip with a first solution of biotin. Comprising language requires that the first solution must at least contain biotin, but does not foreclose the presence of additional elements. The claim language thus encompasses solutions containing biotin-PEG. If the method does not work with additional elements, then the language of the claim should be close ended (i.e., “consisting of”). Secondly, while Applicant argues the molecular weight is important, this is not at all a claimed feature. Applicant asserts that the PEG is required to support the biotin, yet provides no explicit evidence that the reference “teaches away” from the use of biotin alone. In response to Applicant’s argument, the Examiner provides the BOC Sciences, What is Biotinylation and Biotinylated PEG? Article, which does not constitute a new ground of rejection. The BOC Sciences reference discloses that biotinylated PEG can be successfully attached to “surfaces, nanoparticles, antibodies, or other biomolecules to create targeted and stable bioconjugates for imaging, drug delivery, diagnostics, and other biomedical applications”. BOC Sciences states: “A key advantage of using biotinylated PEG is its ability to enhance the stability and biocompatibility of bioconjugates. The hydrophilicity of PEG helps protect the bioconjugate from nonspecific interactions with proteins, cells, and other biological components. This stealth effect, often referred to as the "PEGylation" effect, can improve the circulation time of bioconjugates in the body, reduce immunogenicity, and enhance their therapeutic efficacy.” Thus, without evidence to the contrary, and given that the instant claims fully encompass solutions comprising biotin-PEG, the rejection is maintained for reasons of record. Regarding the new limitation of claim 1 (“wherein the avidin in the second solution is in a second concentration ranging from 30 to 100 µg/mL”), while Applicant asserts that the 30 to 100 ug/mL concentration is critical, the specification does not demonstrate this because throughout the disclosure it is stated “wherein the avidin in the second solution is in a second concentration ranging from 0.1 to 100 μg/ml” (see paragraphs [0013], [0016]) and the working examples teach avidin alexa fluor 488 at, for example, 0.1, 1, 10, 30, and 50 μg/ml (paragraph [0040]). The prior art differs from the claimed invention only with respect to concentration of avidin. The Court has stated that, generally, such differences amount to mere optimization and will not support patentability unless there is evidence indicating the claimed feature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). In KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), the Supreme Court held that "obvious to try" was a valid rationale for an obviousness finding, for example, when there is a "design need" or "market demand" and there are a "finite number" of solutions. 550 U.S. at 421. MPEP 2144 sets forth Applicant' s burden for rebuttal of a prima facie case of obviousness based upon routine optimization. Applicant must provide either a showing that the particular amount or range recited within the claims is critical; and/or a showing that the prior art reference teaches away from the claimed amount. In the instant case, the specification as filed provides no evidence that the particular amount or range recited within the claims is critical because throughout the disclosure and the original claims a broader range of concentrations of avidin is disclosed. Further, Applicant does not persuasively demonstrate that the prior art in any way teaches away from the claimed ranges. Therefore, the rejection is maintained because the method for preparing the biochip of the invention is obvious in view of methods for assembling biochips disclosed in art prior to the effective filing date of the application. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to STACEY NEE MACFARLANE whose telephone number is (571)270-3057. The examiner can normally be reached M-F 7:30-5 (EST) & Sat. A.M.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /STACEY N MACFARLANE/Examiner, Art Unit 1675 /KIMBERLY BALLARD/Primary Examiner, Art Unit 1675
Read full office action

Prosecution Timeline

Dec 29, 2022
Application Filed
Mar 24, 2023
Response after Non-Final Action
Nov 07, 2025
Non-Final Rejection (signed) — §103
Jan 05, 2026
Non-Final Rejection mailed — §103
Mar 20, 2026
Response Filed
May 26, 2026
Non-Final Rejection mailed — §103
Aug 03, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773459
METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX
4y 4m to grant Granted Oct 27, 2026
Patent 12760107
FELINE ANTIBODY VARIANTS
4y 0m to grant Granted Oct 13, 2026
Patent 12736545
METHODS FOR APOLIPOPROTEIN DETECTION
8y 0m to grant Granted Sep 15, 2026
Patent 12736526
Three-Dimensional Human Neural Tissues for CRISPR-Mediated Perturbation of Disease Genes
6y 11m to grant Granted Sep 15, 2026
Patent 12736546
Methods, Systems, and a Kit for Diagnosis, Detection, Monitoring & Treatment of Traumatic Brain Injury
5y 3m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
54%
Grant Probability
93%
With Interview (+39.7%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 843 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month